FLFrancisco J. Luquero

Francisco J. Luquero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francisco J. Luquero has a total of 325 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Côte d’Ivoire

    by Erica Simons, Birgit Nikolay, Pascal Ouedraogo, Estelle Pasquier, Carlos Tiemeni, Ismael Adjaho, Colette Badjo, Kaouther Chamman, Mariam Diomandé, Mireille Dosso, et al.

    Although seroprevalence studies have demonstrated the wide circulation of SARS-COV-2 in African countries, the impact on population health in these settings is still poorly understood. Using representative samples of the general population, we evaluated retrospective mortality and seroprevalence of anti-SARS-CoV-2 antibodies in Lubumbashi and Abidjan. The studies included retrospective mortality surveys and nested anti-SARS-CoV-2 antibody prevalence surveys. In Lubumbashi the study took place during April-May 2021 and in Abidjan the survey was implemented in two phases: July-August 2021 and October-November 2021. Crude mortality rates were stratified between pre-pandemic and pandemic periods and further investigated by age group and COVID waves. Anti-SARS-CoV-2 seroprevalence was quantified by rapid diagnostic testing (RDT) and laboratory-based testing (ELISA in Lubumbashi and ECLIA in Abidjan). In Lubumbashi, the crude mortality rate (CMR) increased from 0.08 deaths per 10 000 persons per day (pre-pandemic) to 0.20 deaths per 10 000 persons per day (pandemic period). Increases were particularly pronounced among <5 years old. In Abidjan, no overall increase was observed during the pandemic period (pre-pandemic: 0.05 deaths per 10 000 persons per day; pandemic: 0.07 deaths per 10 000 persons per day). However, an increase was observed during the third wave (0.11 deaths per 10 000 persons per day). The estimated seroprevalence in Lubumbashi was 15.7% (RDT) and 43.2% (laboratory-based). In Abidjan, the estimated seroprevalence was 17.4% (RDT) and 72.9% (laboratory-based) during the first phase of the survey and 38.8% (RDT) and 82.2% (laboratory-based) during the second phase of the survey. Although circulation of SARS-CoV-2 seems to have been extensive in both settings, the public health impact varied. The increases, particularly among the youngest age group, suggest indirect impacts of COVID and the pandemic on population health. The seroprevalence results confirmed substantial underdetection of cases through the national surveillance systems.


  • Open Access

    Cholera outbreaks in sub-Saharan Africa during 2010-2019: A Descriptive Analysis

    by Qulu Zheng, Francisco J Luquero, Iza Ciglenecki, Joseph F. Wamala, Abdinasir Abubakar, Placide Welo, Mukemil Hussen, Mesfin Wossen, Sebastian Yennan, Alama Keita, et al.

    Background Cholera remains a public health threat, but is inequitably distributed, especially affecting areas without universal access to safe water and sanitation, including much of sub-Saharan Africa. Lack of standardized reporting and inconsistent outbreak definitions limit our understanding of cholera outbreak epidemiology. Methods We curated a database of cholera incidence and mortality from sub-Saharan Africa from 2010 to 2020 and developed methods to reconstruct epidemic curves. We then described the distribution of key outbreak metrics, including outbreak size and duration. Results We identified 999 suspected cholera outbreaks in 744 unique regions across 25 sub-Saharan Africa countries, and outbreak periods accounted for 1.8 billion person-months (2% of the total during this period) from January 2010 through January 2020. Among the 692 outbreaks reported from second-level administrative units (e.g., districts), the median attack rate was 0.8 per 1,000 people (IQR, 0.3-2.4 per 1,000), the median epidemic duration was 13 weeks (IQR, 8-19), and the median early outbreak reproductive number was 1.8 (range, 1.1-3.5). Rural outbreaks had more than twice the case fatality risk than urban ones (median of 1.8% versus 0.8%). Larger attack rates were associated with longer times to outbreak peak, longer epidemic durations, and lower case fatality risks. Conclusions Despite reporting gaps and the limitations of analyzing outbreaks by administrative units, this work provides a baseline from which to monitor progress towards cholera control and essential statistics to inform outbreak management and emergency response in sub-Saharan Africa. Evidence before this study We used PubMed to search for relevant studies published between 2010 and 2019, using the term “Cholera AND (Outbreak OR epidemic) AND (Africa OR Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cabo Verde OR Cameroon OR Central African Republic OR Chad OR Comoros OR Congo Democratic Republic of the OR Congo, Republic of the OR Cote d’Ivoire OR Djibouti OR Egypt OR Equatorial Guinea OR Eritrea OR Eswatini OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome and Principe OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR South Africa OR South Sudan OR Sudan OR Tanzania OR Togo OR Tunisia OR Uganda OR Zambia OR Zimbabwe)”. Of 544 results, 137 were either not about cholera outbreaks or were about cholera outbreaks in a particular country or context and 407 were not about cholera outbreaks. The remaining three were a review of cholera outbreaks in Africa by Martin et al, who focused on general epidemiology and biology of cholera outbreaks before 2011; a review of epidemiology of cholera by Jacqueline et al, who explored the duration, case fatality rate, genomics, risk factors and surveillance of outbreaks across Africa before 2017; and a study of recurrent outbreaks in Africa by Abraham et al, who examined the historical trends, risk factors, burden, severity and control strategies of outbreaks by geographic regions based on available reports from January, 1970 through August, 2017. In addition, a summary table developed by Médecins Sans Frontières (MSF) for cholera outbreak management and response in the field provided major outbreak characteristics (e.g., attack rate, duration, time to outbreak peak) in rural settings, urban settings and slums, and closed situations (e.g., refugee camps) based on a review of cholera epidemics between 1990 and 1997. Added value of this study Previous reviews based on available outbreak reports reflect restricted summaries of outbreak characteristics. To present a comprehensive and up-to-date summary for outbreaks in sub-Saharan Africa, we examined key outbreak features by applying a systematic outbreak definition to time series from a large cholera incidence database. To our knowledge, this is the largest centralized source of global cholera incidence and mortality data. We identified 999 suspected cholera outbreaks in 744 sub-national regions across 25 countries in sub-Saharan Africa, where 2% or 1.8 billion person-months of the total population were living in regions with ongoing outbreaks in the period from 2010 through 2019. In addition, our results suggest that population density may not be universally associated with more severe outbreak outcomes. Compared to historical summaries from MSF, our estimates of attack rates and CFRs are much lower in both rural and urban settings, while the estimate of proportion of cases reported during the peak week is slightly higher, leading to only one-third to one-fourth of the previous estimation of peak bed capacity. Implications of all the available evidence Cholera remains a public health threat in sub-Saharan Africa. This summary of the characteristics and transmission dynamics of outbreaks occurring in sub-Saharan Africa in the period from 2010 through 2019 increases our understanding of cholera outbreak epidemiology and serves as a practical source for future outbreak management and response. As several sub-Saharan African countries have started to developed country plans to reduce cholera incidence in the coming years, our study emphasizes the importance of improving cholera monitoring and surveillance (e.g., laboratory confirmation and finer geographic scale of reporting) in order to identify finer-scale outbreaks, estimate the true burden of cholera and target interventions with limited resources.


  • Open Access

    Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya

    by Etienne Gignoux, Frida Athanassiadis, Ahmed Garat Yarrow, Abdullahi Jimale, Nicole Mubuto, Carole Déglise, Denis Onsongo Mosoti, Andrew S Azman, Matilu Mwau, Francisco Luquero, et al.

    Background Camps of forcibly displaced populations are considered to be at risk of large COVID-19 outbreaks. Low screening rates and limited surveillance led us to conduct a study in Dagahaley camp, located in the Dadaab refugee complex in Kenya to estimate SARS-COV-2 seroprevalence and, mortality and to identify changes in access to care during the pandemic. Methods To estimate seroprevalence, we conducted a cross-sectional survey among a sample of individuals (n=587) seeking care at the two main health centres and among all household members (n=619) of community health workers and traditional birth attendants working in the camp. We used a rapid immunologic assay (BIOSYNEX® COVID-19 BSS [IgG/IgM]) and adjusted for test performance and mismatch between the sampled population and that of the general camp population. To estimate mortality, we exhaustively interviewed all households (n=12860) in the camp about deaths occurring from January 2019 through March 2021. Results We included 1206 participants in the seroprevalence study. In total, 8% (95% CI: 6.6%-9.7%) had a positive serologic test. After adjusting for test performance and standardizing on age, we estimated a seroprevalence of 5.8% (95% CI: 1.6%-8.4%). The mortality rate for 10,000 persons per day was 0.05 (95% CI 0.05-0.06) prior to the pandemic and 0.07 (95% CI 0.06-0.08) during the pandemic, representing a significant 42% increase (pConclusion We estimated that the number of infected people was 67 times higher than the number of reported cases. Participants aged 50 years or more where among the most affected. The mortality survey shows an increase in the mortality rate during the pandemic compared to before the pandemic. A decline in attendance at health facilities was observed and sustained despite the easing of restrictions. What is already known? At the early stage of the COVID-19 pandemic, models predicted the risk of a large-scale COVID-19 outbreaks in camps of forcibly displaced populations that would have created excess mortality caused directly by the disease and indirectly by reduced access to care and/or congestion in health facilities. To date, this prediction has not materialized in most camps, the lower than expected number of cases and deaths could be attributed to a population characteristics and early implementation of confinement; alternatively, it could be an underestimate caused by limited screening and testing capacity and lack of morbidity and mortality surveillance. The actual impact of COVID-19 on these populations therefore remains an open question. What are the new findings? In Dagahaley camps in Kenya, we estimated that the number of infected people was 67 times higher than the number of reported cases. Participants aged 50 years and over, who are most at risk of severe illness, were among the most affected. We observed an increase in mortality rates during the pandemic, and a decrease in the use of health facilities, which continued despite the easing of restrictions, but access for severe cases was less impacted. What do the new findings imply? To our knowledge, this is the first combined survey of COVID-19 seroprevalence and retrospective mortality in a forcibly displaced population living in a camp. Despite mitigation measures, the virus has circulated, which should prompt rapid vaccination as most of the population remains susceptible; the collateral effects of the pandemic on access to care must be addressed and public confidence restored in order to limit the risk of excess mortality. The varying situations of forcibly displaced populations living in camps around the world support the need for further research at other sites.

  • Open Access

    Snakebite Epidemiology in Humans and Domestic Animals Across Nepal's Terai: A Multi-Cluster Random Survey

    by Gabriel Alcoba, Sanjib Kumar Sharma, Isabelle Bolon, Carlos Ochoa, Sara Babo Martins, Manish Subedi, Bhupendra Shah, Anup Ghimire, Etienne Gignoux, Francisco Luquero, et al.

    Background: Each year, two million people worldwide suffer snakebite envenoming (SBE), resulting in up to 138,000 deaths. The World Health Organization has added SBE to the list of Neglected Tropical Diseases, calling for stronger epidemiological evidence in highly endemic countries such as Nepal. Methods: We conducted a cross-sectional survey in 249 randomly selected clusters across Nepal’s Terai region, including 13,879 geospatially selected households. We analysed snakebite incidence rates and outcomes in humans and domestic animals. Findings :Among 63,454 human participants, 166 suffered snakebites over the previous 12 months; 48·8% were envenomed and 7·8% died. This corresponded to annual incidence rates of 262 snakebites [95% CI 225–305] , 127 envenomings [102–158], and 20 [12–35] deaths per 100,000 individuals, extrapolating into 37,661 yearly victims [32,362–43,836] and 2,949 deaths [1,728–5,053] in the Terai. Victim median age was 30 years (IQR 20–45) and 60% were female. Children younger than 15 years (n=6; 46%) and females (n=10; 77%) were over-represented among the 13 deceased. Incidence was higher in Eastern, and mortality in Central regions. Of 184,999 animals, owners reported 144 snakebites, with annual incidence rates of 42-202 and mortality of 79-100 per 100,000 varying by animal type. Spatial and seasonal incidence were similar in humans and animals. Conclusion: This first One Health study on snakebite across Nepal’s Terai shows high incidence and mortality rates in humans and animals. These results call for strengthening of preventive measures and better access to life-saving treatments. Funding: Swiss National Science Foundation project 315130_176271 (SNAKE-BYTE) Declaration of Interest: None to declare. Ethical Approval: The study was approved by the Nepal Health Research Council (NHRC Reg. 585/2018), and Commission Cantonale d’Ethique de la Recherche Scientifique in Geneva, Switzerland (CCER/SwissEthics Registry No. 2018-01331).


  • Open Access

    Successive epidemic waves of cholera in South Sudan, 2014 - 2017

    by Forrest K Jones, Joseph F Wamala, John Rumunu, Pinyi Nyimol Mawien, Kol Mathew Tut, Shirlee Wohl, Lul Deng, Lorenzo Pezzoli, Linda Haj Omar, Justin Lessler, et al.

    Background: Between 2014 and 2017, successive cholera epidemics occurred in South Sudan within the context of civil war, population displacement, flooding, and drought. Understanding the determinants of cholera spread in complex settings like this can provide valuable insights for mitigating future cholera risk. Methods: We analyzed cholera linelist and molecular data to describe the spatio-temporal progression of the epidemics. We explored the role of rainfall, population movement and vaccination campaigns in shaping the explaining incidence and the spatial distribution of reported cases. Findings: South Sudan experienced three distinct cholera epidemic waves of cholera ranging from 6-18 months with more than 28,000 cases reported and more than 2 million cholera vaccine doses delivered to curb transmission. The 2014 and 2015 epidemics remained spatially limited while the 2016/17 epidemic exploded along the Nile river. Initial cases of each epidemic were reported in or around Juba soon after the start of the rainy season, but we found no evidence that rainfall modulated transmission during each epidemic. All isolates analyzed had similar genotypic and phenotypic characteristics, closely related to sequences from Uganda and Democratic Republic of Congo. The direction of large-scale population movements between counties with cholera outbreaks was consistent with the spatial distribution of outbreaks. As of September 2020, zero cholera cases have been confirmed within South Sudan since 2017. Interpretation: The three epidemic waves were caused by V. cholerae of the same clonal origin despite the periods of no reported cases between waves. While the complex emergency likely shaped some of the observed spatial and temporal patterns of reported cases, the full scope of transmission determinants remains unclear. Timely and well targeted use of cholera vaccine can avert cases and deaths, however, most of the vaccine campaigns occurred after the epidemic peak highlighting the challenges of delivering vaccines quickly in response to an outbreak in settings like South Sudan. These analyses provide a multi-faceted template for examining cholera dynamics through epidemiological, microbiological, climatic, and behavioral lenses. Funding: The Bill and Melinda Gates Foundation


  • Open Access

    High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France

    by Thomas Roederer, Bastien Mollo, Charline Vincent, Birgit Nikolay, Augusto Llosa, Robin Nesbitt, Jessica Vanhomwegen, Thierry Rose, François Anna, Corinne Torre, et al.

    Background: A nationwide lockdown was implemented in France on 17 March 2020 to control the COVID-19 pandemic. People living in precarious conditions were relocated by the authorities to emergency shelters, hotels and large venues. Médecins sans Frontières (MSF) then intervened to provide medical care in several of these locations in Paris and in Seine-Saint-Denis, one of its suburbs, between March and June 2020. A seroprevalence survey was conducted to assess the level of exposure to COVID-19 among the population living in the sites. To our knowledge, this is the first assessment of the impact of the pandemic on populations living in insecure conditions in Europe. Methods: We conducted a cross-sectional seroprevalence study in the food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis, to determine the extent of COVID-19 exposure as determined by SARS-CoV2 antibody seropositivity. The detection of SARS-COV2 antibodies in serum was performed at the Institut Pasteur of Paris using two LuLISA (Luciferase-Linked Immunosorbent Assay) assays and a Pseudo Neutralization Test. A questionnaire covering sociodemographic characteristics, living conditions, adherence to sanitary recommendations and symptom manifestations was also completed. We describe here the seroprevalence site by site and identify the risk factors for seropositivity using a multivariable logistic regression model with site random effects. We also investigated associations between seropositivity and symptoms eventually reported. Findings: Overall, 426/818 individuals tested positive in the 14 sites investigated. Seroprevalence varied significantly with the type of site (chi 2 p<0.001). It was highest at 88.7% (95%CI 81.8-93.2) among individuals living in workers’ residences, followed by 50.5% (95%CI 46.3-54.7) in emergency shelters and 27.8 % (95%CI 20.8-35.7) among individuals recruited from the food distribution sites. Seroprevalence also varied significantly between sites of the same type. Among other risk factors, the odds for seropositivity were higher among individuals living in crowded sites (medium: adj. OR 2.7, 95%CI 1.5-5.1, p=0.001; high: adj. OR 3.4, 95%CI 1.7-6.9, p<0.001) compared with individuals from low crowding sites and among those who reported transit accommodation in a gymnasium before the lockdown (adj. OR 3.1, 95%CI 1.2-8.1, p=0.023). More than two-thirds of the seropositive individuals (68.3%; 95%CI 64.2-72.2) did not report any symptoms during the recall period. Interpretation: The results demonstrate rather high exposure to SARS-COV-2 with important variations between study sites. Living in crowded conditions was identified as the most important explanatory factor for differences in levels of exposure. This study describes the key factors which determine the risk of exposure and illustrates the importance of identifying populations at high risk of exposure in order to orient and adapt prevention and control strategies to their specific needs.


  • Open Access

    Persistence of the T12 Vibrio cholerae O1 lineage in West Africa: Insights from a Regional Sequencing Workshop

    by Eme Ekeng, Serges Tchatchouang, Blaise Akenji, Bassira Boubacar Issaka, Ifeoluwa Akintayo, Christopher Chukwu, Ibrahim Dan Dano, Sylvie Melingui, Ousmane Sani, Michael Oladotun Popoola, et al.

    We sequenced 46 Vibrio cholerae isolates from Cameroon, Niger, and Nigeria, 37 of which were from 2018–2019. These sequences belong to the T12 lineage observed in the region since 2009, suggesting continuous transmission. Data were generated during a workshop in Nigeria, providing a model for future regionally coordinated surveillance efforts.

  • Open Access

    Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward

    by Juliet E. Bryant, Andrew S. Azman, Matthew J. Ferrari, Benjamin F. Arnold, Maciej F. Boni, Yap Boum, Kyla Hayford, Francisco J. Luquero, Michael J. Mina, Isabel Rodriguez-Barraquer, et al.

    Defining acceptable performance characteristics for SARS-CoV-2 serological tests requires factoring in how the results will be used.


  • Open Access

    Vibrio Cholerae O1 Transmission in Bangladesh: Insights from a Nationally-Representative Serosurvey

    by Andrew S Azman, Stephen Lauer, M. Taufiqur Rahman Bhuiyan, Francisco J Luquero, Daniel T Leung, Sonia Hegde, Jason B Harris, Kishor Kumar Paul, Fatema Khaton, Jannatul Ferdous, et al.

    Background: Pandemic Vibrio cholerae from cholera-endemic countries around the Bay of Bengal regularly seed epidemics globally. Without reducing cholera in these countries, including Bangladesh, global cholera control may never be achieved. Little is known about the geographic distribution and magnitude of V. cholerae O1 transmission nationally. Here we use recent advances in cholera seroepidemiology to describe infection risk across Bangladesh overcoming many of the limitations of current clinic-based surveillance. Methods: We tested serum from a nationally-representative serosurvey in Bangladesh of 2,778 participants with eight V. cholerae -specific assays. Using these data with a previously validated machine learning model we estimate the annual seroincidence rate and use Bayesian geostatistical models to create high-resolution national maps of infection risk. Findings: We estimate a national seroincidence rate of 19.1% (95% CI 12.2-26.9%). Our high-resolution maps reveal large heterogeneity of infection risk, with community-level annual infection risk within the sampled population ranging from 2.4-69.0%. Across the country, we estimate that 31.0 million (95% CI 19.8-43.7 million) occurred in the year before the survey with most of these infections occurring in urban areas, including Dhaka, the capital. Interpretation: Serosurveillance provides an avenue for identifying areas with high V. cholerae O1 transmission and exploring key risk factors for infection across geographic scales. This may serve as an important tool for countries to plan and monitor progress towards 2030 cholera elimination goals.


  • Open Access

    High cholera vaccination coverage following emergency campaign in Haiti: Results from a cluster survey in three rural Communes in the South Department, 2017

    by Ashley Sharp, Alexandre Blake, Jérôme Backx, Isabella Panunzi, Robert Barrais, Fabienne Nackers, Francisco Luquero, Yves Gaston Deslouches, Sandra Cohuet

    Oral cholera vaccine (OCV) has increasingly been used as an outbreak control measure, but vaccine shortages limit its application. A two-dose OCV campaign targeting residents aged over 1 year was launched in three rural Communes of Southern Haiti during an outbreak following Hurricane Matthew in October 2016. Door-to-door and fixed-site strategies were employed and mobile teams delivered vaccines to hard-to-reach communities. This was the first campaign to use the recently pre-qualified OCV, Euvichol. The study objective was to estimate post-campaign vaccination coverage in order to evaluate the campaign and guide future outbreak control strategies. We conducted a cluster survey with sampling based on random GPS points. We identified clusters of five households and included all members eligible for vaccination. Local residents collected data through face-to-face interviews. Coverage was estimated, accounting for the clustered sampling, and 95% confidence intervals calculated. 435 clusters, 2,100 households and 9,086 people were included (99% response rate). Across the three communes respectively, coverage by recall was: 80.7% (95% CI:76.8–84.1), 82.6% (78.1–86.4), and 82.3% (79.0–85.2) for two doses and 94.2% (90.8–96.4), 91.8% (87–94.9), and 93.8% (90.8–95.9) for at least one dose. Coverage varied by less than 9% across age groups and was similar among males and females. Participants obtained vaccines from door-to-door vaccinators (53%) and fixed sites (47%). Most participants heard about the campaign through community ‘criers’ (58%). Despite hard-to-reach communities, high coverage was achieved in all areas through combining different vaccine delivery strategies and extensive community mobilisation. Emergency OCV campaigns are a viable option for outbreak control and where possible multiple strategies should be used in combination. Euvichol will help alleviate the OCV shortage but effectiveness studies in outbreaks should be done. After Hurricane Matthew hit Southern Haiti on October 4, 2016, there was an outbreak of Cholera. The Government launched a campaign to vaccinate residents using an oral vaccine, which has been proven to protect people against the disease. MSF supported the campaign in three rural areas, offering the vaccine in local clinics and going from door to door. We didn’t know how many people were living there at the time so we couldn’t say for sure if we had vaccinated enough people. To find out how many people were vaccinated we did a survey, choosing households at random and asking them if and where they received the vaccine. This showed that on average around 90% of people were vaccinated, which is a very high proportion. We can take encouragement from this that mass vaccination campaigns like this can work well, even in rural settings. Our survey showed that about half of people got their vaccine from a clinic and the other half from door-to-door vaccinators, so it’s probably important to use both approaches. Most people heard about the campaign through members of the local community called ‘criers’. This shows how important it is to engage with the local community during a vaccination campaign.